



**New Hampshire AIDS Drug Assistance Program
Prior Authorization Drug Approval Form**

Winrevair™ (sotatercept-csrk)

DATE OF MEDICATION REQUEST: / /

SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

GENDER:

☐ Male

☐ Female

Drug Name:

Strength:

Dosing Directions:

Length of Therapy:

SECTION II: PRESCRIBER INFORMATION

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FAX NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SECTION III: CLINICAL HISTORY

1. Does the patient have pulmonary arterial hypertension (PAH) WHO group 1? ☐ Yes ☐ No

2. Has the diagnosis been confirmed by right heart catheterization? ☐ Yes ☐ No

If yes, provide documentation.

3. Provide the following values attached or in the space provided.

Pulmonary arterial pressure: _____

Pulmonary capillary wedge pressure: _____

Pulmonary vascular resistance: _____

4. Is the patient's PAH considered functional class II or greater? ☐ Yes ☐ No

Phone: 1-800-424-7901

Fax: 1-800-424-7984

© 2025 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Review Date: 06/05/2025





**New Hampshire AIDS Drug Assistance Program
Prior Authorization Drug Approval Form**

Winrevair™ (sotatercept-csrk)

DATE OF MEDICATION REQUEST: / /

5. Has the patient been on stable background PAH therapy for at least 90 days? ☐ Yes ☐ No
If yes, list the medications and start dates.

6. Is the patient a female of reproductive potential? ☐ Yes ☐ No
If yes, will pregnancy be ruled out before therapy begins? ☐ Yes ☐ No

Will the patient be educated on contraceptive needs during therapy and for at least 4 months after therapy ends? ☐ Yes ☐ No

7. Will hemoglobin and platelets be monitored throughout therapy? ☐ Yes ☐ No
Provide the baseline platelet count: _____

8. Is the prescriber a cardiologist or pulmonologist, or has one been consulted? ☐ Yes ☐ No

RENEWAL:

1. Has the patient experienced any treatment-restricting adverse effects? ☐ Yes ☐ No
2. Has the patient benefited from the medication through disease improvement, stabilization, or improvement in the slope of decline? ☐ Yes ☐ No

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: _____ **DATE:** _____